secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001213900-25-001156
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics to effect 1-for-100 reverse stock split to cure Nasdaq bid price deficiency
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-100 ratio effective Jan 8, 2025; reduces outstanding shares from ~260M to ~2.6M.
- Company received Nasdaq delisting notice on Oct 24, 2024 after bid price ≤$0.10 for ten consecutive days.
- Company presented compliance plan to Nasdaq on Dec 17, 2024; believes reverse split will cure deficiency.
- No fractional shares issued; stockholders entitled to fractional shares will round up to whole share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/ea0226772-8k_cerotherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer